Article
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study.
The oncologist - 5 Jan 2024
Incorvaia Lorena, De Biase Dario, Nannini Margherita, Fumagalli Elena, Vincenzi Bruno, De Luca Ida, Brando Chiara, Perez Alessandro, Pantaleo Maria A, Gasperoni Silvia, D'Ambrosio Lorenzo, Grignani Giovanni, Maloberti Thais, Pedone Erika, Bazan Russo Tancredi Didier, Mazzocca Alessandro, Algeri Laura, Dimino Alessandra, Barraco Nadia, Serino Roberta, Gristina Valerio, Galvano Antonio, Bazan Viviana, Russo Antonio, Badalamenti Giuseppe
Abstract excerpt
BACKGROUND: The patient selection for optimal adjuvant therapy in gastrointestinal stromal tumors (GISTs) is provided by nomogram based on tumor size, mitotic index, tumor location, and tumor rupture. Although mutational status is not currently used to risk assessment, tumor genotype showed a prognostic influence on natural history and tumor relapse. Innovative measures, such as KIT/PDGFRA-mutant-specific variant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
